Friday, December 12, 2008

More about Joint Commission’s disruptive behavior policy

Chris Rangel wrote a provocative post about Joint Commission’s new disruptive behavior policy set to go into effect in 2009. He’s concerned that the definition of disruptive behavior (for which the JC recommends a zero tolerance policy) is a little vague, particularly this language (italics mine):

Intimidating and disruptive behaviors include overt actions such as verbal outbursts and physical threats, as well as passive activities such as refusing to perform assigned tasks or quietly exhibiting uncooperative attitudes during routine activities. Intimidating and disruptive behaviors are often manifested by health care professionals in positions of power. Such behaviors include reluctance or refusal to answer questions, return phone calls or pages; condescending language or voice intonation; and impatience with questions.

He points out:

Wait a minute! What this second part means is that basically, if you are having a bad day, then you’re a disruptive physician. If you have a bad bedside manner or you are not chummy with the hospital staff then you are disruptive. If you are distracted by a personal or professional crisis, then you are being disruptive. As one AMA delegate put it, if you are perceived as being disruptive to any particular staff member then you ARE disruptive.

By this definition a hospital administration could invoke the disruptive behavior policy to sanction anyone they don’t happen to like.

He goes on to point out an important unintended consequence of such a policy, which is to suppress strong opinions and concerns about hospital operations which may impact patient care. As I first noted here, such whistle blowing on the part of physicians, even legitimate expressions of concern, may be construed as disruptive.

He concludes:

The JC shouldn’t be trying to codify specific behaviors. Each case is unique and should be decided without specific description of behaviors leading to unfair bias while loosing sight of the endpoint of this whole endeavor. Neither should we expect every person in a high stress job where people’s lives are on the line to walk around like a smiling jackass in some hall monitor’s idea of the perfect Stepford Wives-like medical nightmare where everyone is pleasant and totally incompetent. Given the choice, I’d rather be treated by the brilliant asshole* then Dr. Smiley Mannequin. So far the AMA has asked the JC to reconsider their proposal. Let’s hope that the JC grows some CS.

While I agree with Rangel for the most part he failed to mention that the new JC policy is no respecter of persons---it applies equally to nurses, pharmacists, doctors and administrators. There’s no double standard. Everyone in the health care environment is expected to be civil. It’s not just about doctors anymore. As I pointed out in a recent post Alan H. Rosenstein, MD, MBA, an expert who has written a great deal on this subject, said that many doctors are the recipients rather than the perpetrators of disruptive behavior.


The Joint Commission, much to its credit, recognizes that fact. The Sentinel Event Alert regarding the new standard is careful to avoid the term “disruptive physician” and says:

While most formal research centers on intimidating and disruptive behaviors among physicians and nurses, there is evidence that these behaviors occur among other health care professionals, such as pharmacists, therapists, and support staff, as well as among administrators.

The report recommends several actions including (italics mine):

Educate all team members – both physicians and non-physician staff – on appropriate professional behavior defined by the organization’s code of conduct.

Hold all team members accountable for modeling desirable behaviors, and enforce the code consistently and equitably among all staff regardless of seniority or clinical discipline…

If you’ve worked in a hospital for any length of time you know that this disruptive behavior thing works both ways. That’s why I’m more than a little disappointed in the New York Times distortion of the issue in their recent article Arrogant, Abusive and Disruptive — and a Doctor. It’s a one sided portrayal of the stereotypical instrument throwing physician who intimidates everyone else on the health care team:

Still, every nurse has a story about obnoxious doctors. A few say they have ducked scalpels thrown across the operating room by angry surgeons. More frequently, though, they are belittled, insulted or yelled at — often in front of patients and other staff members — and made to feel like the bottom of the food chain. A third of the nurses in Dr. Rosenstein’s study were aware of a nurse who had left a hospital because of a disruptive physician.

With JC’s broad definition of disruptive behavior applied across the whole spectrum of health care providers the possibilities are endless. If a nurse grudgingly carries out a doctor’s orders, if an attending leans a little too heavily on a medical student or if administration is unreceptive to expressed concerns about patient care, one can invoke the disruptive behavior policy.

Thursday, December 11, 2008

American Academy of Pediatrics statement on CAM

About the only thing informative about this report from the AAP is its documentation of the spread of woo like a cancer throughout academic and community medicine. Otherwise it’s pretty much a fluff piece, or so it seems to me.

Walmart’s generic drug list

Seems there’s never a copy around when I need one, so I’ll link it here.

Wednesday, December 10, 2008

Change coming to the White House

You mean it won’t be smoke free anymore? Who knew?



Not much mainstream coverage about this, but some bloggers have weighed in.

Dr. Wes

Happy Hospitalist

BOSO


I mean, it’s all about leading by example for the public good, right?

Lotrel outdoes Lotensin/HCTZ in ACCOMPLISH

This was a high risk population of hypertensives. The study was published in NEJM. Despite nearly identical BP control, outcomes were better in the Lotrel group:

There were 552 primary-outcome events in the benazepril–amlodipine group (9.6% and 679 in the benazepril–hydrochlorothiazide group (11.8%), representing an absolute risk reduction with benazepril–amlodipine therapy of 2.2% and a relative risk reduction of 19.6% (hazard ratio, 0.80, 95% confidence interval [CI], 0.72 to 0.90; P<0.001).

In a Medscape piece concerning the study Dr Franz Messerli commented:

"This landmark study unequivocally relegates hydrochlorothiazide from first-line to third-line therapy at least in a patient population with similar demographic and clinical features as in ACCOMPLISH," said Messerli. "The issue is not to be taken lightly, since hydrochlorothiazide remains one of the most commonly prescribed antihypertensive drugs….”

Venous thromboembolism and pregnancy

---is reviewed in NEJM. Very comprehensive and helpful.

Monday, December 08, 2008

Maybe I could get excited about palliative care

---if someone would tell me what it is.

Bob Wachter describes a wonderful clinical service at UCSF---one that is well organized, delivers excellent care and is rated highly by patients, families and house staff. He calls it the palliative care service but doesn’t quite define what it is, leaving me wondering about the whole concept. Think I’m nit picking? Try asking your colleagues, or searching the literature on what palliative care really is. Good luck in getting a coherent answer.

Even the usually straightforward Wikpedia is vague, describing palliative care as something which is delivered in the context of both curative care and hospice care. So what is it, exactly?

Bob’s post is not explicit but from his title (My Patients Are Dying… And I’ve Never Been Prouder) he’s talking about end of life care. But Mount Sinai School of Medicine Professor R. Sean Morrison, MD, who has written a great deal about palliative care, said in a recent Medscape video editorial that “Unlike hospice, hospital palliative care is not dependent on prognosis.” Moreover, in an earlier NEJM article Morrison’s description of palliative care does not preclude curative care as implied by this statement: “Palliative care should be offered simultaneously with all other medical treatment.” In this recently published study the majority of patients on palliative care services were discharged alive. So, again, what is it?

The closest thing you’ll find to a definition (and it’s not really satisfactory) is something like the one in the NEJM article:

Palliative care aims to relieve suffering and improve the quality of life for patients with advanced illnesses and their families through specific knowledge and skills, including communication with patients and family members; management of pain and other symptoms; psychosocial, spiritual, and bereavement support; and coordination of an array of medical and social services.

OK. Palliation means making the patient’s illness get better while paying attention to the surrounding psycho-social and spiritual issues. It’s what we should be doing for all our patients all the time, so why does a hospital need a special service? (The focus on patients with advanced illness doesn’t really narrow things down much; most hospitalized patients have advanced illness). My reading suggests that palliative care is simply hospital medicine raised to a higher level of excellence, efficiency, organization and patient centeredness. It sounds a lot like what the Institute of Medicine has been harping at all of us to do. The idea of a palliative care “program” suggests a separate team to deliver this excellent care while the rest of us settle for mediocrity! Palliative care claims to have distinctive attributes, but they really shouldn’t be distinctive. They should be the norm.

A common thread in many descriptions of palliative care relates to the quality of communication. Discussions go beyond DNR status and whether the patient has a living will to the education of patients and families on the big picture of the patient’s health and realistic expectations concerning the limitations of treatment. This leads to greater patient satisfaction, more informed and rational decision making, and often the avoidance of ICU care, feeding tubes and other technologies which, in many patients, serve only to decrease quality of life. While these interventions are ineffective in many patients they are costly, which is probably why palliative care programs save hospitals money. Lots of money. But again, why should good communication with patients and families require a special care service?

Like so many other concepts in medicine, the word “palliative” has been hijacked. The idea of palliative care has been administratively defined by people with agendas. For clinicians it’s been an exercise in obfuscation.

The excellence and the efficiency of what is called palliative care is something to get excited about. It’s something we should all strive for. I would like to see our hospitalist program spearhead a multidisciplinary effort to take these ideas to a new level of excellence for all of patient care. But I don’t think I’d call it palliative care. I’d call it something else. I’m not sure what, but something with more meaning.

Sunday, December 07, 2008

Cardiac precautions for methadone prescribing

Some guidelines are finally out, issued by the American College of Physicians. Medscape provides a summary here. Among the recommendations:

Recommendation 1 (Disclosure): When clinicians prescribe methadone, they should inform patients about arrhythmia risk.

Recommendation 2 (Clinical History): Clinicians should ask patients about any history of structural heart disease, arrhythmia, or syncope.

Recommendation 3 (Screening): All patients should have a pretreatment electrocardiogram (ECG) to measure QTc interval and a follow-up ECG within 30 days and each year.

I wonder how many people are actually doing this. I started harping about it way back here.

Google hacks

A slide presentation is presented here via Clinical Cases and Images blog.

Also check out these resources.

Here’s one of my old posts on Google vs PubMed.

Saturday, December 06, 2008

Should doctors interact with drug reps?

That’s the topic of the latest Medscape Roundtable Discussion. I took the libertarian view: Let individual doctors decide for themselves.

Friday, December 05, 2008

Drug induced nephropathy

American Family Physician has a review and some recommendations. Unfortunately the journal is no longer open access so I can’t link to the article (not even the abstract). But here’s a Medscape CME piece which summarizes the review. (Fair and balanced? Yes, as far as I can tell, and no industry support!).

This issue has garnered increasing recent attention in hospital medicine. The new emphasis is on lowering the threshold for detecting renal injury. Changes in serum creatinine formerly considered modest should prompt a review of medications and a search for means to mitigate renal damage.

Thursday, December 04, 2008

Rapid response teams disappoint---again

This may be the biggest study yet, from St. Luke’s, Kansas City, MO.

Conclusion In this large single-institution study, rapid response team implementation was not associated with reductions in hospital-wide code rates or mortality.

Performance does not equal quality

DB in a recent rant explains why performance measures don’t translate into quality. He says the boosters have pulled a fast one on us by confusing performance with real quality. I have to agree. Let’s call the performance measures what they are---performance measures, not quality measures.

One of his commenters gently takes him to task:

The best we can do is to continually test the relationships between “quality measures” at all levels and the final results we desire. Waiting for perfect measures is unrealistic.

I have to ask: if you don’t think guidelines should be followed in the populations for whom they are designed (which is how we identify the denominator populations for Bernoulli-distributed process measures), with whom are you really arguing?

I suppose the alternative is to reject empiricism entirely and adopt the framework of Cartesian doubt.

I don’t read DB as knocking EBM, or even guidelines, although he has been critical of the way they are promoted. My take is that today’s performance measures have little to do with true EBM. Moreover the performance police, in an effort to get everyone on board with a minimum standard of guideline based care, have misappropriated and over simplified those same guidelines.

Wednesday, December 03, 2008

A six hour ER wait time

---is better than six months. That’s why many patients, even insured patients, are going to the ER for their primary care. Read about it in Kevin’s USA Today op-ed.

ALLHAT hype

It’s not the way science is supposed to work. You don’t go out and hype your results after they are published. A research publication should stand, in the arena of scientific discussion and critical examination, on its own merits. But that’s not the way the ALLHAT steering committee looked at things. From the moment of its publication the study was spun and promoted like the latest woo.
ALLHAT did change practice. Thiazide prescriptions increased following its publication, but apparently not enough, according to the New York Times, to suit the boosters:

“It should have more than doubled,” said Dr. Curt D. Furberg, a public health sciences professor at Wake Forest University who was the first chairman of the steering committee for the study, which was known by the acronym Allhat. “The impact was disappointing.”

What was the vested interest in hyping ALLHAT? Some of the lead investigators, together with the media, seeking to advance the premise that pharmaceutical industry marketing had set back the cause of science in the treatment of hypertension, saw the study as a gigantic “see we told you so.”

Sure there were lessons in ALLHAT for the treatment of hypertension but the hype surrounding the study distracted us from a reasoned critical analysis of the findings. The message of the promoters, that thiazide diuretics were, plainly and simply, the starting drugs of choice for hypertension, went way beyond the study findings. There were serious concerns about the design, execution and interpretation of ALLHAT which I won’t belabor here. DB dealt with them in his blog as I did in these pages.

Some time ago on I cited concerns about the metabolic hazards of thiazides and a documented risk of sudden cardiac death. A recent meta-analysis, showing a similar trend towards increased sudden death, added to the concern. The senior investigator, renowned hypertension expert John Oates, said:

“If it's true, it's probably the largest adverse effect in the history of modern pharmacology. The number of individuals affected over the last 50 years would be staggering.”

The trend, while coming short of statistical significance, would be enough for the media to blow a new proprietary drug out of the water. The New York Times was silent.

Although thiazides, as I explained here, do have a very important role in the treatment of hypertension, the notion that thiazide monotherapy is the unequivocal first step in hypertension treatment was not supported by ALLHAT and now, we know, is just plain wrong.

Tuesday, December 02, 2008

All that wheezes is not asthma

About a third of patients who carried a diagnosis of asthma turned out not to have asthma at all in this study. A related editorial makes the point that underdiagnosis as well as overdiagnosis of asthma is common, and the major error is failure to do spirometry.

I wish the paper had provided the real diagnoses of the patients who didn’t have asthma. An interview with one of the authors suggests that many of these patients had an acute viral illness with bronchospasm, were declared to have asthma and never formally tested or tapered off their medications.

Monday, December 01, 2008

If my patient gets an infection it’s somebody else’s fault

I found this ad in the ICU lounge:




It reflects our new culture. The patient safety movement purported to replace a culture of blame with one of transparency and constructive system change. But the movement’s obsession with “never events”, aided and abetted by popular media, has had the opposite effect. I’m afraid this is headed in the wrong direction.

Making sense of the guidelines: pneumonia

I am reposting my 11/03/08 pneumonia guideline summary because the categories need clarification. Updated comments are italicized.

The pneumonia guidelines are complicated. They consist of two sets of guidelines (community acquired pneumonia, CAP, and health care associated pneumonia, HCAP) which are distinct but have just enough overlap to be confusing. Both guidelines stratify patients into high and low resistance risk groups. The respective groups are similar in the two guidelines with distinctions that seem nit picking and at times don’t make sense. (Why, for example, is ceftazidime listed as an antipseudomonal drug in the HCAP guideline but not the CAP guideline?). Add to this the criteria for site of care (home vs ward vs ICU) and de-escalation (PO switch, discharge and stopping therapy). Who can remember it all? You can look it up each time---the guidelines are open access full text---but opening up and browsing those large pdf files is cumbersome.

Is it worth the trouble? Although guidelines are not a substitute for clinical judgment, you may ignore them at your patients’ peril. In the case of pneumonia it has been shown repeatedly (here, here, here, here, here, and here) that guideline adherence is associated with better outcomes.

Here is my attempt to remedy pneumonia guideline chaos by condensing the essentials in one post. The figures below summarize the information I find my self looking up most often. (The complete guidelines should be read in their entirety, once or twice. They contain a world of information on etiology, pathogenesis and diagnosis, not covered here).


Hospital acquired pneumonia (HAP), ventilator associated pneumonia (VAP) and health care associated pneumonia (HCAP) are listed in the guidelines as separate categorizations. Among these three categories, however, the antibiotic recommendations are based on microbiologic risk and are the same for a given level of risk. Therefore, for purposes of this guideline summary I have lumped the three categories together as HCAP.

A practical definition of HCAP which encompasses all three categories is pneumonia with any one of the following characteristics: onset 48 hours or more after admission; two or more days of acute care hospitalization in the past 90 days; nursing home residency; IV antibiotic therapy, chemotherapy or wound care within the past 30 days; hemodialysis. Other pneumonias would be considered community acquired pneumonia (CAP).

After adjudicating a patient as CAP or HCAP go to the appropriate section below to assign microbiologic risk. Note that conditions defining a patient as “HCAP” and “HCAP, high microbiologic risk” overlap greatly but are not interchangeable. Rigid application of some distinctions becomes nit picking. Clinical judgment and common sense are required.

The fourth line under the category HCAP, high microbiologic risk should read “two or more days of hospitalization in the last 90 days.”






Note: The above table classifies CAP and HCAP according to the risk of resistant organisms. CAP is also independently classified as to eligibility for ICU placement. Aside from the obvious indications of shock and mechanical ventilation, guideline recommendations for ICU placement include patients with any 3 of: RR 30 or above; PO2/FiO2 250 or below; multilobar infiltrates; acute alteration in mental status; BUN 20 or above; WBC below 4000; platelet count below 100,000; hypothermia (core below 36C); hypotension requiring fluid challenge.








Admission decisions can be based on the CURB-65 criteria or the pneumonia severity index.

Miscellaneous: No time rule for antibiotic admin; guidelines say give in ER. Legionella and pneumococcal urine antigen determinations are recommended for many, but not all, categories of patients. For CAP, blood cultures are considered optional in some of the lowest risk patients.

New evidence post guideline publication: Steroids for severe CAP? Maybe; stay tuned. Statins? Promising. CA-MRSA is a bad actor, and is emerging. Think of it.

Primary biliary cirrhosis review

From the Orphanet Journal or Rare Diseases.